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Abstract
The aim of this study was to investigate pre- and post-diagnostic use of antihypertensive
drugs on prostate cancer (PCa)-specific survival and the initiation of androgen deprivation
therapy (ADT). The cohort investigated 8,253 PCa patients with 837 PCa-specific deaths
during the median follow-up of 7.6 years after diagnosis. Information on drug use, cancer
incidence, clinical features of PCa, and causes of death was collected from Finnish regis-
tries. Hazard ratios with 95% confidence intervals were calculated using Cox regression
with antihypertensive drug use as a time-dependent variable. Separate analyses were per-
formed on PCa survival related to pre- and post-diagnostic use of drugs and on the initiation
of ADT. Antihypertensive drug use overall was associated with an increased risk of PCa-
specific death (Pre-PCa: 1.21 (1.04–1.4), Post-PCa: 1.2 (1.02–1.41)). With respect to the
separate drug groups, angiotensin II type 1 receptor (ATr) blockers, were associated with
improved survival (Post-PCa: 0.81 (0.67–0.99)) and diuretics with an increased risk (Post-
PCa: 1.25 (1.05–1.49)). The risk of ADT initiation was slightly higher among antihyperten-
sive drug users as compared to non-users. In conclusion, this study supports anti-cancer
effect of ATr blockers on PCa prognosis and this should be investigated further in controlled
clinical trials.
Introduction
Prostate cancer (PCa) is the most common cancer in men [1]. Known risk factors for PCa are
age, race, and a family history of PCa. Hypertension has been suggested as a risk factor for PCa
progression [2–4]. However, hypertension is linked to other factors such as metabolic syn-
drome—thus, it is difficult to distinguish the impacts of underlying risk factors, hypertension
and its medication on PCa development and progression. As in many other cancers, PCa
involves re-programmed normal cellular functions, such as glucose- and cholesterol metabo-
lism, in cancer progression [5]. Thus, commonly used drugs affecting normal cellular
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functions such as drugs targeting the renin-angiotensin system (RAS), fluid homeostasis, and
the sympathetic nervous system may influence PCa progression.
In particular, the role of RAS in cancer development and progression has been under inves-
tigation [6, 7]. In mice, treatment with angiotensin II receptor blockers decreased the volume
of a prostate tumor. However, administration of angiotensin II had no effect on tumor size [8].
On the other hand, angiotensin II has increased prostate cell viability in different cell models
[9, 10].
Results on antihypertensive drug use and PCa-specific mortality are controversial [11–18].
In general, the evaluation of use of different antihypertensive drug groups is challenging due
to the heterogeneity of drug users. Furthermore, differentially acting drug groups are com-
monly used in parallel to achieve blood pressure control.
Recently, we showed that the use of antihypertensive drugs is moderately associated with an
increased risk for prostate cancer in a comprehensive population-based cohort study based on
the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC). The risk increase
was not related to any specific drug group [19]. Here we have investigated whether pre- and
post-diagnostic use of any antihypertensive drug group associates with PCa-specific survival.
Furthermore, we evaluated the risk of PCa progression by using initiation of androgen-depri-
vation therapy (ADT) as a surrogate.
Materials and methods
Study cohort
The original study cohort, FinRSPC, involved 80,458 men aged 55–67 years old at study entry
from Tampere and Helsinki areas in Finland [20]. All men were free of PCa at baseline. By the
end of 2016, 8,253 men were diagnosed with prostate cancer and information was available on
their drug use. These men formed our study population. The Finnish Cancer Registry, which
covers 96% of all solid tumor cases, provided information on cancer diagnoses [21]. Data on
Gleason scores, TNM stage, and prostate cancer-specific antigen (PSA) level at the time of
diagnosis was obtained from medical records. The Cause of Death registry in Statistics Finland
houses information on causes of death (TK-53-1330-18) and the Care Register for Health Care
provided information on diagnoses and medical procedures in secondary and tertiary health
care units. Unique personal identification number, assigned to all Finnish citizens, was used in
a deterministic linkage to combine information from the registries and medical records.
Causes of death were classified using the International Classification of Diseases (ICD-10)
codes; PCa was considered the cause of death when the underlying cause was C61 and deaths
from cardiovascular disease (CVD) included codes I20-I25, I30-I52, and I70-I79. During
2004–2008, a questionnaire about height, weight, and use of non-prescription drugs, such aspi-
rin and other non-steroidal anti-inflammatory drugs (NSAIDs) was mailed to participants still
in the study. Originally, information on Body Mass Index (BMI) was collected from 11,698
subjects [22], and in the current study population, this was available for 805 men.
Information on medication use
The prescription database of Social Insurance Institution (SII) of Finland was used to collect
information on the use of antihypertensive drugs from 1996 to 2016. As a part of the national
health insurance, SII provides reimbursements for purchases of physician-prescribed drugs to
all Finnish citizens. All reimbursements are recorded in the database including the purchase
date, drug dose, number of doses in the package, and number of drug packages for each pur-
chase. In Finland, all antihypertensive drugs are available only by prescription, thus all pur-
chases, except drugs for hospital patients, are recorded.
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Drug-specific Anatomic Therapeutic Chemical (ATC) codes were used to identify the med-
ications and were divided according to mechanism of action into angiotensin-converting
enzyme (ACE) inhibitors, angiotensin II receptor (ATr) blockers, beta-blockers, calcium chan-
nel blockers, and diuretics. Additional information on purchases of statins, antidiabetic drugs,
5-alpha-reductase inhibitors, and prescription aspirin and other NSAIDs was also collected.
The diuretics analyzed included only those drugs used for hypertension. Thus, loop-diuretics
and spironolactone, commonly used for edema and fluid retention problems, were excluded.
Defined Daily Dose (DDD) [23] was used to calculate standardized cumulative doses by
dividing annual amount of purchased drug by drug-specific DDD-values. All DDDs in each
group were calculated together and value presented as annual cumulative doses of each drug
group. The number of years with recorded drug purchases was used to calculate cumulative
years of drug use. By dividing cumulative doses by cumulative years, average annual doses, i.e.
average intensities of the drug use were calculated. Risk trends were analyzed by stratifying the
study population by tertiles of intensity, DDD-values, and years of the drug use (termed low,
medium and high use).
Statistical analysis
Hazard ratios (HR) and their 95% confidence intervals (CI) for prostate cancer-specific mor-
tality were estimated using Cox regression models. The time metric was months and years
from diagnosis. Each antihypertensive drug group was analyzed as a time-dependent variable,
except pre-diagnostic use which was analyzed as a time-fixed variable (thus subjects were clas-
sified as either ever-users or never-users before the diagnosis). Purchases were used to deter-
mine annually cumulative use for each follow-up year for each drug group. Subjects stayed as
non-users until the first antihypertensive drug purchase and after that, they remained as ever-
users for the whole follow-up period. This minimized bias due to selective discontinuation of
medication in the terminal phase of cancer. Analysis of overall antihypertensive drug use was
conducted separately. Different drug groups were included into models simultaneously as sep-
arate time-dependent variables, to enable modelling of mutually adjusted simultaneous use of
several antihypertensive drugs. Lag-time analysis was conducted by lagging the diagnosis of
PCa by one or three years from different drug use.
To evaluate whether antihypertensive drug use exerted any impact on the progression of
cancer, the risk for initiation of androgen deprivation therapy (ADT) was analyzed using a
Cox regression model, where follow-up started at PCa diagnosis and continued until ADT ini-
tiation, death/emigration, or the end of 2016. The analysis was limited only for long-term
ADT treatment, participants who also had radiation therapy as primary management in addi-
tion to ADT were excluded.
Analyses were performed for risk overall and separately for subgroups of Gleason grade 7
and 8–10, risk group 2 (for definition see below), and metastatic cancers. The risk for all-cause
mortality was calculated without subgroup analyses. All analyses were adjusted for age,
FinRSPC trial arm (screening arm and control arm), year of diagnosis, cancer clinical charac-
teristics (T stage, metastasis, and Gleason grade), Charlson comorbidity index, use of statins,
antidiabetic drugs, anticoagulants, 5-alpha-reductase inhibitors, aspirin and other NSAIDs.
Sensitivity analysis by adjusting the model by marital and socioeconomical status, and BMI
were conducted with subgroup in whom information was available. We also conducted sensi-
tivity analysis by number of used drugs (one, two, or three or more) and combination of differ-
ent drug groups (e.g. ATr blockers + diuretics). PCa risk groups were created based on
Gleason grade, clinical characteristics and tumor extent: risk group 0 included cases where
Gleason grade was 6, T-stage was 1 or 2, or PSA was less than 10 μg/l, risk group 1 included
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cases where Gleason grade was 7, T-stage was 3, or PSA was 10–20 μg/l and risk group 2
included cases where Gleason grade was 8 or more, T-stage was 4, cancer was metastatic, or
PSA was more than 20 μg/l. Charlson comorbidity index was calculated as explained previ-
ously [24]. All analyses were performed using IBM SPSS statistical software (version 24).
We performed competing risks analysis to estimate association between antihypertensive
drug groups and PCa-specific death, with deaths from cardiovascular disease (CVD) as the
competing risk. Deaths due to non-cancer and non-CVD causes were censored. The model
was adjusted for age, FinRSPC trial arm, year of diagnosis, PCa risk group, Charlson comor-
bidity index, use of statins, antidiabetic drugs, anticoagulants, 5-alpha-reductase inhibitors,
aspirin, and other NSAIDs. The analysis was done using StataCorp Stata Statistics (version
14.0).
Results
Population characteristics
The majority (79%) of the study population had at least one antihypertensive drug purchase
during the follow-up (Table 1). Of the 8,253 prostate cancer cases, 2,479 had Gleason grade 7
and 1,379 Gleason 8 or above, 2284 patients belonged to risk group 2, and 589 had metastatic
cancer. The median follow-up time was 7.6 years after diagnosis. The median age at diagnosis
was 68 years. In total, 2,765 subjects died during the follow-up, including 837 deaths from PCa
(Table 1). The overall PCa-specific death rate after diagnosis was 13.3 per 1000 person-years. It
was 12.0 among users and 20.2 in non-users (Table 1). Of the specific drug groups, PCa-spe-
cific mortality after diagnosis was highest among users of diuretics (11.7 deaths per 1000 per-
son-years) and lowest among users of ATr blockers (8 per 1000) (Table 1).
The users of antihypertensive drugs also had been prescribed other drugs more often than
non-users (p<0.001) (Table 1). Non-users had slightly lower BMI values. There was no differ-
ence in the distribution of FinRSPC study arms or age at diagnosis between the groups (68 or
69 years in all groups). The follow-up time was slightly shorter in the group of non-users, how-
ever, it was similar between all other groups (Table 1).
Risk of prostate cancer-specific death by antihypertensive drug use
Both pre- and post-diagnostic use of antihypertensive drugs was associated with an increased
risk for PCa-specific death compared to non-users in multivariable-adjusted analysis (HR
1.21, 95% CI 1.04–1.4 and HR 1.2, 95% CI 1.02–1.41, respectively) (Fig 1, Table 2). In addition,
the risk for all-cause mortality was higher among users of antihypertensive drugs (Pre: HR
1.38, 95% CI 1.27–1.5, Post: HR 1.33, 95% CI 1.21–1.47) (Table 3A). As expected, the risk of
CVD-specific deaths was elevated in users of antihypertensive drugs (Pre: HR 1.96 95% CI
1.61–2.39, Post: HR 2.57, 95% CI 1.97–3.36) (Table 3B).
When antihypertensive drug groups were analyzed separately, post-diagnostic use of ATr
blockers was associated with a decreased risk for PCa death (HR 0.81, 95% CI 0.67–0.99) (Fig
1, Table 2). The risk decrease was observed also for pre-diagnostic use (HR 0.74, 95% CI 0.58–
0.96). Pre- and post-diagnostic use of diuretics was associated with an increased risk of death
from PCa (Pre: HR 1.31, 95% CI 1.07–1.6, Post: HR 1.25, 95% CI 1.05–1.49) (Fig 1, Table 2).
Tumor characteristics did not modify the risk associations by the use of ATr blockers or
diuretics (Fig 2, Table 2).
Furthermore, pre-diagnostic use of ATr blockers was associated with a decreased all-cause
mortality (Table 3A). On the other hand, the use of beta-blockers and ACE inhibitors was
associated with increased all-cause mortality (Table 3A). Other investigated antihypertensive
drug group did not associate with the risk of PCa-specific or all-cause mortality (Fig 1,
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Tables 2 & 3A). The use of beta-blockers and ACE inhibitors also associated with elevated
CVD mortality (Table 3B). Diuretics and calcium channel blockers displayed no association
with deaths from CVD.
Adjustments of the model by socioeconomical and marital status, and BMI did not modify
the risk associations. Lagging the PCa diagnosis by one or three years after drug use did not
reveal any statistically meaningful association with prostate cancer-specific mortality
(S3 Table).
Table 1. Population characteristics. Cohort of 8253 men with prostate cancer (PCa) from the Finnish Randomized Study of Screening for Prostate Cancer. ACE
inhibitors = angiotensin-converting enzyme inhibitors; ATr blockers = angiotensin II receptor type.
All Non-users Users ACE inbitors ATr blockers Beta-blockers Calcium
channel
blockers
Diuretics
NO. of PCa cases 8253 1875 (22.7) 6378 (77.3) 3297 (39.9) 2316 (28.1) 4467 (54.1) 3172 (38.4) 2397 (29)
Gleason 7 n (%) 2479 (30) 539 (28.7) 1940 (30.5) 990 (30.0) 694 (30.0) 1355 (30.3) 958 (30.2) 705 (29.4)
Gleason 8–10 n (%) 1379 (16.7) 345 (18.4) 1034 (16.2) 510 (15.5) 352 (15.2) 705 (15.8) 464 (14.6) 361 (15.1)
Risk group 2 n (%) 2284 (27.7) 559 (29.8) 1725 (27) 877 (26.6) 560 (24.2) 1211 (27.1) 811 (25.6) 627 (26.2)
Metastatic ceses n (%) 589 (7.1) 180 (9.6) 409 (6.4) 208 (6.3) 99 (4.3) 277 (6.2) 173 (5.5) 141 (5.9)
Hormonal therapy n (%) (excluded
cases where radiation therapy was
combined with ADT)
2120 (25.7) 483 (25.8) 1637 (25.7) 872 (26.4) 469 (20.3) 1149 (25.7) 764 (24.1) 581 (24.2)
Median age at time of randomization
(IQR)
63 (59–63) 59 (55–63) 63 (59–67) 63 (59–67) 59 (59–63) 63 (59–67) 63 (59–67) 63 (59–67)
Median age at time of diagnosis (IQR) 68 (64–72) 68 (64–72) 69 (65–72) 68 (64–72) 68 (64–72) 69 (65–73) 68 (65–72) 68 (64–72)
Follow-up time after randomization,
median (IQR)
12 (11–13) 12 (11–13) 12 (11–13) 12 (11–13) 12 (11–13.4) 12 (11–13) 12 (11–13) 12 (11–13)
Follow-up time after diagnosis, median
(IQR)
7.6 (3.8–
11.1)
5.9 (2.8–
10.3)
8 (4.2–11.3) 8.4 (4.6–11.8) 8.7 (4.8–11.8) 8.1 (4.3–11.5) 8.5 (4.7–11.7) 8.9 (5–12)
Deaths n (%) 2765 (33.5) 622 (33.2) 2143 (33.6) 1148 (34.8) 663 (28.6) 1587 (35.5) 1042 (32.8) 805 (33.6)
PCa-specifin deaths n (% from all
deaths)
837 (30.2) 224 (36) 613 (28.6) 308 (26.8) 162 (24.4) 415 (26.1) 271 (26) 249 (30.9)
PCa-specifin deaths per 1000 person-
years after diagnosis
13.3 20.2 12.0 11.1 8.0 11.5 10.1 11.7
CVD-specific deaths n (% from all
deaths)
586 (21.2) 66 (10.6) 520 (8.2) 328 (28.6) 175 (26.4) 420 (26.5) 259 (24.9) 197 (24.4)
Median BMI (IQR) (n) 26.24
(24.22–
28.67) (805)
25.06
(23.54–
27.17) (197)
26.59 (24.55–
28.73)
(608)���
26.6 (24.4–
29.0)
(277)���
27.1 (25.0–
29.1)
(242)���
27.0 (24.9–
29.1)
(391)���
26.9 (24.9–
29.1) (299)���
27.74 (25.42–
30.05) (202)
FinRSPC arm
Screening n (%) 3425 (41.5) 797 (42.5) 2628 (41.2) 1391 (42.2) 934 (40.3) 1855 (41.5) 1318 (41.6) 962 (40.1)
Control n (%) 4828 (58.5) 1078 (57.5) 3750 (58.8) 1906 (57.8) 1382 (59.7) 2612 (58.5) 1854 (58.4) 1435 (59.9)
Use of other drugs
Statins n (%) 3870 (46.9) 408 (21.8) 3462 (54.3)��� 1913
(58.0)���
1383
(59.7)���
2604
(58.3)���
1825 (57.5)��� 1382 (57.7)���
Antidiabetic drugs n (%) 1599 (19.4) 118 (6.3) 1481 (23.3)��� 915 (27.8)��� 608 (26.2)��� 1130
(25.3)���
853 (26.9)��� 617 (25.7)���
NSAIDs n (%) 7065 (85.6) 1534 (81.8) 5531 (86.7)��� 2821
(85.6)���
2058
(88.9)���
3881
(86.9)���
2771 (87.4)��� 2107 (87.9)���
Aspirin n (%) 1143 (13.8) 139 (7.4) 1004 (15.7)��� 522 (15.8)��� 404 (17.4)��� 760 (17.0)��� 528 (16.6)��� 374 (15.6)���
5-alpha-reductase inhibitors n (%) 1229 (14.9) 224 (11.9) 1005 (15.8)��� 495 (15.0)��� 381 (16.5)��� 717 (16.1)��� 499 (15.7)��� 390 (16.3)���
Anticoagulants n (%) 4275 (51.8) 585 (31.2) 3690 (57.9)��� 2050
(62.2)���
1370
(59.2)���
2895
(64.8)���
1867 (58.9)��� 1388 (57.9)���
https://doi.org/10.1371/journal.pone.0234269.t001
PLOS ONE Antihypertensive drugs and prostate cancer-specific mortality
PLOS ONE | https://doi.org/10.1371/journal.pone.0234269 June 29, 2020 5 / 15
Sensitivity analysis by number of used drugs did not modify the results as risk for PCa-spe-
cific death was increased similarly despite number of drug groups in use (S5 Table). Some
drug combinations showed slightly different survival associations compared to main analysis;
combination of beta-blockers and diuretics were associated with lowered risk of PCa death
compared non-users (HR 0.74, 95% CI 0.57–0.96) whereas diuretics and beta-blockers in com-
bination were associated with increased risk (HR 2.36, 95% CI 1.89–2.94). Other drug group
combination did not show significant associations with PCa-specific survival (S5 Table).
Risk trends by cumulative antihypertensive drug use
In the risk trend analysis for the post-diagnostic use of ACE inhibitors, the risk for PCa death
tended to decrease with the amount of use, but the trend was not statistically significant
(Table 4). Among ATr blocker users, the strongest risk decrease was observed in the tertile of
highest intensity of use (over 559.2 DDDs annually) regardless of cancer grade and stage
(Table 4). No clear dose-dependent risk trends were observed by pre-diagnostic use for either
drug group (S1 Table). Risk trend analyses for tertiles of post-diagnostic DDD-values and
years of use can be found in the supplemental material (S2 Table).
Risk for initiation of androgen deprivation therapy
Any use of antihypertensive drugs was associated with a slightly increased risk for initiation of
ADT as compared to non-users (HR 1.15, 95% CI 1.05–1.27) (Table 4). The risk increase was
seen also in Gleason 8–10 and risk group 2 tumors (Table 5). When different drug groups
were compared, only use of ACE inhibitors and beta blockers showed increased risks (HR
1.21, 95% CI 1.09–1.35, and HR 1.1, 95% CI 1–1.21, respectively). Such associations were not
seen in the subgroups of clinical tumor characteristics (Table 5). Drug groups did not reveal
any meaningful dose-dependent association with the risk of initiation of ADT (S4 Table).
Competing risk analysis
The risk association for the pre-diagnostic use antihypertensive drug use was similar in com-
peting risk analysis as in the main analysis; use of ATr blockers continued to be associated
with improved disease-specific survival (HR 0.74, 95% CI 0.57–0.98) and the use of diuretics
slightly increased the risk (HR 1.25, 95% CI 1.01–1.54).
Fig 1. Association of prostate cancer (PCa)-specific mortality and pre- and post-diagnostic use of different
antihypertensive drugs. Data is presented as hazard ratios (HR) with 95% confidence intervals (CI).
https://doi.org/10.1371/journal.pone.0234269.g001
PLOS ONE Antihypertensive drugs and prostate cancer-specific mortality
PLOS ONE | https://doi.org/10.1371/journal.pone.0234269 June 29, 2020 6 / 15
Discussion
We evaluated prostate cancer-specific and all-cause mortality by pre- and post-diagnostic anti-
hypertensive drug use in a Finnish cohort study consisting of men living in metropolitan areas
Table 2. Risk for prostate cancer (PCa)-specific mortality of pre- and post-diagnostic use of antihypertensive drugs compared to non-users after PCa diagnosis.
Cox regression hazard model was adjusted with age, FinRSPC trial arm (screening arm and control arm), year of diagnosis, cancer clinical characteristics (T stage, metasta-
sis, and Gleason grade), Charlson comorbidity index, use of statins, antidiabetic drugs, anticoagulants, 5-alpha-reductase inhibitors, aspirin and other NSAIDs. ACE
inhibitors = angiotensin-converting enzyme inhibitors; ATr blockers = angiotensin II receptor type 1 blockers; HR (95% CI) = hazard ratio and 95% confidence intervals.
PCa-specific death Pre-diagnostic use Post-diagnostic use
Overall risk n of men n of PCa deaths (%) HR (95% CI) HR (95% CI)
Non-users 1875 224 (11.9) ref. ref.
Users 6378 613 (9.6) 1.21 (1.04–1.4) 1.2 (1.02–1.41)
ACE inhibitors 3297 308 (9.3) 1.11 (0.93–1.33) 1.04 (0.88–1.22)
ATr blockers 2316 162 (7) 0.74 (0.58–0.96) 0.81 (0.67–0.99)
Beta-blockers 4467 415 (9.3) 1.18 (1.0–1.39) 1.15 (0.99–1.33)
Calcium channel blockers 3172 271 (8.5) 0.93 (0.78–1.12) 1.01 (0.86–1.19)
Diuretics 2397 249 (10.4) 1.31 (1.07–1.6) 1.25 (1.05–1.49)
Gleason 7
Non-users 539 50 ref. ref.
Users 1940 178 1.69 (1.28–2.26) 1.39 (1–1.94)
ACE inhibitors 1489 130 1.26 (0.89–1.78) 1.26 (0.97–1.76)
ATr blockers 1785 179 0.89 (0.56–1.43) 0.76 (0.53–1.09)
Beta-blockers 1124 111 1.31 (0.96–1.8) 1.07 (0.79–1.44)
Calcium channel blockers 1521 141 0.86 (0.6–1.23) 1.05 (0.78–1.41)
Diuretics 1774 145 1.48 (1.1–2.16) 1.55 (1.13–2.15)
Gleason 8–10
Non-users 345 115 ref. ref.
Users 1034 288 1.05 (0.84–1.31) 1.11 (0.88–1.41)
ACE inhibitors 510 134 1.1 (0.85–1.42) 0.91 (0.72–1.15)
ATr blockers 352 81 0.72 (0.51–1.02) 0.9 (0.68–1.2)
Beta-blockers 705 195 1.14 (0.9–1.45) 1.12 (0.96–1.48)
Calcium channel blockers 464 119 0.98 (0.76–1.26) 1.01 (0.8–1.28)
Diuretics 361 103 1.24 (0.94–1.65) 1.08 (0.8–1.28)
Risk group 2
Non-users 559 179 ref. ref.
Users 1725 426 1.12 (0.94–1.33) 1.1 (0.91–1.33)
ACE inhibitors 1407 214 1.18 (0.95–1.45) 1.1 (0.91–1.33)
ATr blockers 1724 106 0.7 (0.52–0.94) 0.82 (0.65–1.05)
Beta-blockers 1073 282 1.13 (0.94–1.38) 1.08 (0.9–1.23)
Calcium channel blockers 1473 181 0.93 (0.76–1.15) 0.99 (0.82–1.2)
Diuretics 1657 163 1.31 (1.03–1.66) 1.15 (0.93–1.42)
Metastatic disease
Non-users 180 112 ref. ref.
Users 409 213 1.04 (0.82–1.32) 0.95 (0.74–1.22)
ACE inhibitors 381 106 1.38 (1.02–1.85) 1.1 (0.83–1.45)
ATr blockers 490 41 0.73 (0.48–1.12) 0.83 (0.57–1.22)
Beta-blockers 312 131 0.95 (0.73–1.24) 0.93 (0.73–1.19)
Calcium channel blockers 416 87 1 (0.75–1.34) 1.08 (0.82–1.42)
Diuretics 448 67 1.01 (0.73–1.41) 0.89 (0.64–1.23)
https://doi.org/10.1371/journal.pone.0234269.t002
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of Helsinki and Tampere. In general, the use of antihypertensive drugs was associated with
increased PCa-specific and all-cause mortality as compared to non-users. When we evaluated
the different antihypertensive drug groups, post-diagnostic use of RAS-inhibiting drugs, ACE
inhibitors, and AT-receptor blockers were associated with improved survival, whereas diuret-
ics were associated with poorer survival.
The reduction in risk was more pronounced for AT-receptor blockers than for ACE inhibi-
tors. However, only post-diagnostic use of ACE inhibitors showed a dose-dependent risk
trend. Similarly, in a UK population-based cohort, Cardwell et al. [13] revealed that users of
ACE inhibitors and ATr blockers had a slightly decreased PCa-specific mortality and con-
cluded that it was safe to use these antihypertensive drugs after PCa diagnosis. Furthermore,
Ronquist et al. [25] observed that the post-operative captopril users had less biochemical
Table 3. Risk for all-cause mortality (A), and cardiovascular diseases (CVD) mortality of pre- and post-diagnostic use of antihypertensive drugs compared to non-
users after PCa diagnosis. Cox regression hazard model was adjusted with age, FinRSPC trial arm (screening arm and control arm), year of diagnosis, cancer clinical
characteristics (T stage, metastasis, and Gleason grade), Charlson comorbidity index, use of statins, antidiabetic drugs, anticoagulants, 5-alpha-reductase inhibitors, aspirin
and other NSAIDs. ACE inhibitors = angiotensin-converting enzyme inhibitors; ATr blockers = angiotensin II receptor type 1 blockers; HR (95% CI) = hazard ratio and
95% confidence intervals.
A)
All-cause death Pre-diagnostic use Post-diagnostic use
Overall risk n of men n of deaths HR (95% CI) HR (95% CI)
Non-users 1875 622 ref. ref.
Users 6378 2143 1.38 (1.27–1.5) 1.33 (1.21–1.47)
ACE inhibitors 3297 1148 1.22 (1.11–1.34) 1.19 (1.09–1.29)
ATr blockers 2316 663 0.88 (0.77–1) 0.98 (0.89–1.08)
Beta-blockers 4467 1587 1.22 (1.12–1.33) 1.4 (1.28–1.52)
Calcium channel blockers 3172 1024 1.05 (0.96–1.16) 1.07 (0.99–1.17)
Diuretics 2397 805 1.16 (1.05–1.29) 0.97 (0.88–1.07)
B)
CVD death Pre-diagnostic use Post-diagnostic use
Overall risk n of men n of CVD deaths HR (95% CI) HR (95% CI)
Non-users 1875 66 ref. ref.
Users 6378 520 1.96 (1.61–2.39) 2.57 (1.97–3.36)
ACE inhibitors 3297 328 1.52 (1.25–1.85) 1.85 (1.54–2.22)
ATr blockers 2316 175 0.83 (0.64–1.08) 1.26 (1.03–1.54)
Beta-blockers 4467 420 1.67 (1.39–2.02) 2.07 (1.7–2.53)
Calcium channel blockers 3172 259 1.12 (0.92–1.36) 0.88 (0.72–1.06)
Diuretics 2397 197 1.11 (0.9–1.37) 1.13 (0.95–1.36)
https://doi.org/10.1371/journal.pone.0234269.t003
Fig 2. Role of tumor clinical characteristics on PCa mortality among users of any antihypertensive drug, and
separately for angiotensin II receptor blockers (ATr blockers) and diuretics. Data is presented as hazard ratios (HR)
with 95% confidence intervals (CI).
https://doi.org/10.1371/journal.pone.0234269.g002
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Table 4. Risk of prostate cancer (PCa)-specific mortality by the post-diagnostic use of antihypertensive drugs after diagnosis of PCa. Users stratified into tertiles by
cumulative intensity of the use (DDD values/years of the use). Cox regression model was adjusted with age, FinRSPC trial arm (screening arm and control arm), year of
diagnosis, cancer clinical characteristics (T stage, metastasis, and Gleason grade), Charlson comorbidity index, use of statins, antidiabetic drugs, anticoagulants, 5-alpha-
reductase inhibitors, aspirin and other NSAIDs. ACE inhibitors = angiotensin-converting enzyme inhibitors; ATr blockers = angiotensin II receptor type 1 blockers; HR
(95% CI) = hazard ratio with 95% confidence intervals.
ACE inhibitors ATr blockers Beta-blockers Calcium channel blockers Diuretics
Limits
Low <336 <303.2 <100 <261.3 <148.3
Medium 336–676.9 303.2–559.2 100–187.4 261.3–399.4 148.3–217.8
High 676.9> 559.2> 187.4> 399.4> 217.8>
Overall, n
Low 1100 772 1542 1051 790
Medium 1098 772 1436 1064 790
High 1099 772 1489 1057 790
Overall, PCa death risk HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Low 1.16 (0.93–1.45) 0.89 (0.67–1.18) 1.27 (1.04–1.55) 1.18 (0.94–1.48) 1.44 (1.12–1.84)
Medium 1.06 (0.84–1.33) 0.81 (0.6–1.09) 1.29 (1.05–1.6) 0.93 (0.73–1.19) 1.09 (0.82–1.45)
High 0.92 (0.72–1.19) 0.63 (0.45–0.88) 0.97 (0.78–1.21) 1.08 (0.84–1.4) 1.32 (1.02–1.7)
Gleason 7, n
Low 302 201 465 379 240
Medium 337 255 228 408 215
High 351 238 462 315 241
Gleason 7, PCa death risk HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Low 1.15 (0.75–1.78) 0.99 (0.6–1.64) 1.04 (0.71–1.55) 1.11 (0.74–1.65) 1.92 (1.27–2.91)
Medium 1.28 (0.84–1.96) 0.76 (0.44–1.33) 0.92 (0.6–1.42) 1.15 (0.75–1.75) 1.3 (0.78–2.15)
High 1.67 (1.09–2.57) 0.69 (0.37–1.26) 1.17 (0.78–1.74) 0.92 (0.55–1.55) 1.28 (0.79–2.08)
Gleason 8–10, n
Low 168 134 256 288 104
Mediate 178 102 229 226 132
High 164 116 220 116 119
Gleason 8–10, PCa death risk HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Low 1.06 (0.75–1.48) 0.94 (0.63–1.41) 1.58 (1.18–2.12) 1.38 (0.97–1.97) 1.21 (0.81–1.81)
Medium 0.89 (0.63–1.25) 0.85 (0.55–1.31) 1.5 (1.11–2.02) 0.95 (0.65–1.38) 1.02 (0.67–1.55)
High 0.69 (0.47–1.02) 0.58 (0.36–0.95) 0.85 (0.61–1.2) 1.15 (0.81–1.65) 1.24 (0.84–1.83)
Risk group 2, n
Low 287 201 417 476 207
Medium 301 183 394 369 220
High 289 176 400 231 193
Risk group 2, PCa death risk HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Low 1.23 (0.94–1.61) 0.9 (0.64–1.27) 1.28 (1–1.62) 1.17 (0.89–1.54) 1.27 (0.93–1.74)
Medium 1.06 (0.81–1.41) 0.77 (0.53–1.13) 1.25 (0.97–1.62) 0.87 (0.64–1.18) 1.09 (0.78–1.53)
High 1.01 (0.75–1.35) 0.62 (0.41–0.94) 0.91 (0.7–1.19) 1.15 (0.85–1.55) 1.25 (0.91–1.71)
Metastatic cancer, n
Low 77 33 104 154 43
Medium 69 39 91 78 47
High 62 27 82 27 48
Metastatic cancer, PCa death risk HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Low 1.26 (0.86–1.85) 0.91 (0.52–1.61) 1.02 (0.72–1.44) 1.37 (0.93–2.03) 0.79 (0.47–1.33)
Medium 1.24 (0.84–1.83) 0.9 (0.52–1.56) 1.4 (0.98–2) 0.75 (0.46–1.21) 0.83 (0.5–1.38)
High 1.02 (0.67–1.55) 0.42 (0.2–0.88) 0.62 (0.42–0.91) 1.55 (1.02–2.33) 1.29 (0.81–2.07)
https://doi.org/10.1371/journal.pone.0234269.t004
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Table 5. Effect of antihypertensive drugs on initiation of hormonal therapy for treatment of prostate cancer in
Finnish men. Cox regression hazard model was adjusted with age, FinRSPC trial arm (screening arm and control
arm), year of diagnosis, cancer clinical characteristics (T stage, metastasis, and Gleason grade), Charlson comorbidity
index, use of statins, antidiabetic drugs, anticoagulants, 5-alpha-reductase inhibitors, aspirin and other NSAIDs.
ADT = androgen deprivation therapy; ACE inhibitors = angiotensin-converting enzyme inhibitors; ATr
blockers = angiotensin II type 1 receptor blockers; HR (95% CI) = hazard ratio with 95% confidence intervals.
Initiation of ADT
Overall risk n of ADT treated men HR (95% CI)
Non-users 483 ref.
Users 1637 1.15 (1.05–1.27)
ACE inhibitors 872 1.21 (1.09–1.35)
ATr blockers 469 1.05 (0.91–1.21)
Beta-blockers 1149 1.1 (1-1-21)
Calcium channel blockers 764 0.86 (0.76–0.98)
Diuretics 581 1 (0.89–1.11)
Gleason 7
Non-users 298 ref.
Users 958 1.13 (0.94–1.36)
ACE inhibitors 270 1.16 (0.95–1.41)
ATr blockers 141 1.07 (0.83–1.39)
Beta-blockers 356 1.12 (0.94–1.34)
Calcium channel blockers 243 1.05 (0.86–1.29)
Diuretics 335 0.8 (0.62–1.02)
Gleason 8–10
Non-users 219 ref.
Users 548 1.2 (1–1.43)
ACE inhibitors 231 1.22 (0.99–1.5)
ATr blockers 129 1.11 (0.84–1.46)
Beta-blockers 319 1.09 (0.91–1.31)
Calcium channel blockers 205 099 (0.81–1.23)
Diuretics 184 0.92 (0.81–1.23)
Risk group 2
Non-users 360 ref.
Users 952 1.15 (1.01–1.32)
ACE inhibitors 415 1.19 (1.02–1.39)
ATr blockers 208 1.1(0.89–1.36)
Beta-blockers 559 1.04 (0.91–1.2)
Calcium channel blockers 369 0.97 (0.83–1.14)
Diuretics 336 0.91 (0.75–1.1)
Metastatic disease
Non-users 166 ref.
Users 381 1.08 (0.88–1.31)
ACE inhibitors 189 1.09 (0.87–1.38)
ATr blockers 87 0.94 (0.66–1.33)
Beta-blockers 246 1 (0.82–1.22)
Calcium channel blockers 158 1.03 (0.81–1.3)
Diuretics 136 0.96 (0.73–1.27)
https://doi.org/10.1371/journal.pone.0234269.t005
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failures as compared to non-users. However, the study consisted only of 62 patients and the
mean follow-up time was 29 months. Alashkham et al. [26] showed that biochemical recur-
rence was decreased after curative-intent radiotherapy with hormone treatment among users
of RAS-inhibiting drugs as compared to non-users. Our study supports these findings,
although we did not see any reduction in the risk of initiation of ADT therapy among users of
RAS-inhibiting drugs.
Results from analysis of pre-diagnostic use of antihypertensive drugs and PCa-specific sur-
vival was in line with the results of post-diagnostic use: overall antihypertensive drug use was
associated with an increased risk for PCa-specific death, with decreased mortality among users
of ATr blockers and an increase in users of diuretics. Furthermore, pre-diagnostic use of anti-
hypertensive drugs was associated with increased all-cause mortality. This was also seen with
several different drug groups: ACE inhibitors, beta-blockers, and calcium channel blockers,
but not simply ATr blockers. These results underline that, in general, users of antihypertensive
drugs are at an increased risk of death as compared to non-users, but the association is differ-
ent for users of ATr blockers. A similar trend was evident when the association of antihyper-
tensive drugs and CVD-specific deaths was analyzed. The results were similar when deaths
due to CVD were taken into account using competing risk analysis, suggesting that the risk
association with PCa survival was not affected by the higher risk for CVD death among antihy-
pertensive drug users compared to non-users.
The reason why specifically it is the use of ATr blockers that may improve PCa-specific sur-
vival is not clear. In our study, users of ATr blockers had a smaller proportion of metastatic
cancer cases, a lower likelihood of initiation of ADT therapy, and lower PCa mortality as com-
pared to patients in the other groups. This could be due to selective prescribing of this drug
group to healthier men than other antihypertensive drugs, or due to genuine effects of ATr
blockers on PCa. Our results are in line with a recently published study, where the use of ATr
blockers increased PCa-specific survival after radical prostatectomy [18]. ATr blockers are
antagonists of angiotensin II receptor type 1, which mediates the classical angiotensin II-
related effects; vasoconstriction, fluid volume homeostasis, cell proliferation, and fibrosis [27].
Other RAS-inhibiting drugs, ACE inhibitors, inhibit the main angiotensin II forming enzyme,
thus both drug groups block angiotensin II-mediated functions, albeit at different sites in the
pathway. ATr blockers may have some yet unknown mechanism of action impacting on PCa
development and progression. Nevertheless, the possible role of RAS in development and pro-
gression of cancer is under investigation [7,28,29].
Diuretics are commonly used in management of edema, which is common in advanced
cancer. Thus, loop diuretics (furosemide) and spironolactone, which are used in management
of edema rather than hypertension, were excluded from this analysis. Still, the use of diuretics
was associated with an increased risk for PCa death despite lack of association with a higher
stage cancer, such metastatic or risk group 2 cases, which might be expected if increased the
association could be explained by the treatment of end-stage cancer-related problems. In
agreement, Holmes et al. [11] reported an increased risk for PCa-specific deaths among thia-
zide diuretics users. In our study, we did not evaluate the role of separate diuretic classes.
We did not find any association of pre- and post-diagnostic use of beta-blockers with pros-
tate cancer-specific mortality. Previous studies have reported controversial results [14–17].
However, in analyses based on time-dependent variables, as in our study, no association has
been found [30, 31]. However, the use of beta-blockers was associated with a slightly increased
risk for ADT initiation, pointing to some association with tumor progression. In contrast to
our findings, in a Norwegian population-based cohort, Grytli et al. [16] showed that the use of
beta-blockers during ADT-therapy seemed to decrease the risk of PCa-specific death.
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However, that study was analyzed without time-dependent variables. Nevertheless, the link
between beta-blockers and PCa outcomes remains unclear.
A recently published study [32] investigated the role of antihypertensive drug use on PCa-
specific mortality in gonadotropin-releasing hormone agonist users. They showed a slightly
increased PCa mortality in users of blood pressure lowering drugs. We did not have informa-
tion on blood pressure levels and were thus unable to evaluate the role of hypertension in this
risk association.
Our study has several strengths. The Finnish prescription database is comprehensive and
accurate; for example, all reimbursements for purchases of antihypertensive drugs are
recorded, and thus we had nearly complete coverage of our subjects’ drug purchases. Our fol-
low-up time was long enough to enable modeling cumulative simultaneous use of multiple
drugs. We also had comprehensive information of clinical features of prostate cancer, such as
Gleason grade and TNM stage. In addition, information on PCa deaths was collected from an
accurate and reliable nationwide, population-based database that has been validated by an
independent cause of death committee; the validity of information of PCa-specific deaths
between cause of death registry and recording in patients’ medical files was compared and
97.7% agreement (kappa = 0.95) between them was found [33]. Furthermore, statistical power
in our cohort is sufficient to detect clinically meaningful survival differences as our sample size
was sufficient to detect 3.5% survival difference between medication users and non-users with
80% power and risk for type I error being 0.05.
Our study also has some limitations. We did not have information on blood pressure levels
of the subjects or indication for antihypertensive drugs. In addition, data of some background
information, which might be shared risk factors for prostate cancer death and hypertension,
such as smoking habits, were missing. However, we were able to adjust the analysis for the use
of other drugs which might have impacted on the development and progression of PCa, such
as statins [34]. Our drug use data is based on reimbursement for drug purchases. Thus, we do
not know whether the subject actually used the purchased drugs. It should be noted that most
likely the users of antihypertensive drugs have more comorbidities and are at increased risk of
death in general as compared to non-users, possibly affecting also PCa-specific mortality. Fur-
thermore, different antihypertensive drugs are described based on comorbidities and the
health status of the patients which might bias the results.
In conclusion, the use of antihypertensive drugs was associated with an increased risk for
prostate cancer-specific and all-cause mortality. When the analysis was done separately for dif-
ferent drug groups, both pre- and post- diagnostic use of RAS inhibiting drugs, especially ATr
blockers, associated with improved PCa survival in a dose-dependent manner, whereas the use
of diuretics associated with poorer survival. The results might be affected by systematic differ-
ences between the users and non-users. Nevertheless, our findings support previous reports
about the beneficial effects of RAS-inhibition on PCa progression. The role and potential bene-
fits of RAS inhibition in PCa should be examined further.
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